Navigation Links
Regeneron Reports First Quarter 2013 Financial and Operating Results
Date:5/3/2013

TARRYTOWN, N.Y., May 3, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial and operating results for the first quarter of 2013 and provided an update on development programs. 

The Company reported total revenues of $440 million in the first quarter of 2013, compared to $232 million in the first quarter of 2012.  Total revenues include EYLEA U.S. net product sales of $314 million in the first quarter of 2013, compared to $124 million in the first quarter of 2012.  The Company reported non-GAAP net income of $201 million, or $1.78 per diluted share, in the first quarter of 2013, compared to $40 million, or $0.37 per diluted share, in the first quarter of 2012.  Non-GAAP net income excludes non-cash share-based compensation expense, non-cash interest expense related to the Company's convertible senior notes, and non-cash income taxes.  The Company reported GAAP net income of $99 million, or $0.90 per diluted share, in the first quarter of 2013, compared to $12 million, or $0.11 per diluted share, in the first quarter of 2012. 

"The first quarter of 2013 was a productive quarter where we delivered sustained revenue and earnings growth," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  "EYLEA sales in the U.S. continue to enjoy strong growth and we are raising our estimate of full year U.S. EYLEA net sales to $1.25 to $1.325 billion in 2013.  The ex-U.S. launch of EYLEA by our partner, Bayer HealthCare, is also going very well and resulted in a positive contribution to our earnings this quarter.  Our broad, late-stage pipeline is making progress.  We expect our first data from the alirocumab Phase 3 program for reducing LDL cholesterol in the second half of 2013.  We reported positive data with our IL-4R inhibitor, dupilumab, in atopic dermatitis and additional data for dupilumab are expected in allergic ast
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
2. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Regeneron Announces March 2012 Investor Conference Presentations
5. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
7. Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
8. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
9. Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development
10. InterMune Reports First Quarter 2013 Financial Results and Business Highlights
11. Cord Blood Banking Industry: 2013 Growth Opportunities Analysis in New Market Research Report at ReportsnReports.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Jersey (PRWEB) September 30, 2014 ... has been chosen by the Parenteral Drug Association ... 18 and 19, 2014) on container closure integrity testing. ... closure integrity test methods and philosophies detailed in the ... Integrity Evaluation. The course will span container ...
(Date:9/29/2014)... start of the military conflicts in Iraq and Afghanistan, ... States with traumatic brain injury caused by exposure to ... explosive devices, or IEDs. Symptoms of traumatic brain injury ... and nausea, to more severe impairments in memory and ... Defense has recognized the critical importance and complexity of ...
(Date:9/29/2014)... Present-day lithium batteries are efficient but involve a ... from alfalfa (lucerne seed) and pine resin and ... come up with a highly interesting alternative. Their ... journal ChemSusChem . , ,We think our ... energy-efficient solutions for the batteries of the future, ...
(Date:9/29/2014)... Mass. , Sept. 29, 2014  Atlas Venture, ... life sciences and technology innovation, today announced that ... Epizyme (NASDAQ: EPZM ), is joining the ... October 1, 2014. At Atlas, Rhodes will ... groundbreaking companies. He brings an accomplished record in company ...
Breaking Biology Technology:Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4Smart, eco-friendly new battery to solve problems 2Atlas Venture Names Jason Rhodes, Veteran Investor and President and CFO of Epizyme, As Partner on Life Sciences Investing Team 2
... Software, a leading provider of image data management tools for ... Open Microscopy Environment Consortium, is proud that its founder Professor ... this year,s BBSRC Innovator of the Year. The BBSRC is ... in the non-clinical life sciences, and along with the Wellcome ...
... the best education and to absorb what they are ... the journal Academic Medicine * connects research on how ... real world education, particularly the education of doctors. "Repetition, ... knowing what is happening in the brain will enhance teaching ...
... surgeon Dr. Lewis Groden presented results from a ... and Refractive Surgery (ASCRS) Symposium revealing that LASIK procedures ... and very high patient satisfaction rates. Each ... vision center currently offers patients a choice of multiple ...
Cached Biology Technology:Glencoe Software and Open Microscopy Environment Founder Awarded the BBSRC Innovator of the Year 2011 2Brain scientists offer medical educators tips on the neurobiology of learning 2Brain scientists offer medical educators tips on the neurobiology of learning 3Brain scientists offer medical educators tips on the neurobiology of learning 4Brain scientists offer medical educators tips on the neurobiology of learning 5LasikPlus® Research Reveals Excellent Results From Modern LASIK 2
(Date:9/29/2014)... Joint Genome Institute (DOE JGI), a DOE Office ... new projects have been selected for the 2015 ... to Caribbean waters, and from plant root micro-ecosystems, ... forested watersheds, the CSP 2015 projects portfolio highlights ... extracted. , "These projects catalyze JGI,s strategic ...
(Date:9/29/2014)... can DNA from the skeleton of a man who lived ... us about ourselves as humans? A great deal when his ... in genetic terms found to-date in a region where ... ago. , The man,s maternal DNA, or ,mitochondrial DNA, ... and evolution. Mitochondrial DNA provided the first evidence that we ...
(Date:9/29/2014)... CHAMPAIGN, Ill. Scientists have discovered a previously ... divide, grow and, in the case of estrogen-positive ... the work reveals new targets for breast cancer ... need the most aggressive treatment. , The University ... journal Oncogene . , Estrogen pre-activates the ...
Breaking Biology News(10 mins):2015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9Ancient human genome from southern Africa throws light on our origins 2Ancient human genome from southern Africa throws light on our origins 3Scientists discover a new role for estrogen in the pathology of breast cancer 2
... researchers have found that the naturally occurring marine toxin ... in rats exposed to the chemical before birth. Humans ... after eating contaminated shellfish. , The researchers saw ... exposure to domoic acid levels below those generally deemed ...
... (Nasdaq: SLXA) today announced that its researchers in collaboration ... Delaware reported the most comprehensive analysis to date of ... "Elucidation of the Small RNA Component of the Transcriptome," ... the peer-reviewed journal Science. Solexa's assay can be used ...
... Medicine uses PET, radiotracer to track enzyme in smokers, ... in the lungs, possibly contributing to some of smoking's ... the September issue of the Journal of Nuclear Medicine. ... enzyme, also shows that smokers had a lower concentration ...
Cached Biology News:Prenatal exposure to marine toxin causes lasting damage 2Prenatal exposure to marine toxin causes lasting damage 3Solexa and collaborating scientists illuminate the small RNA component of the transcriptome 2Smoking damages key regulatory enzyme in the lung 2Smoking damages key regulatory enzyme in the lung 3
Tumor Suppressor Sampler Kit 10 mu g each...
AMAP Multi Site-directed Mutagenesis Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: dry ice...
Umbilical cord blood eosinophils, For immunohistochemistry (IHC)...
Slide Chambers are convenient for performing pre-hybridization incubations and post-hybridization washes with tissue sections mounted on standard glass microscope slides. Each chamber holds up to 5 s...
Biology Products: